Placeholder

Pramipexole

CAS No:
104632-26-0 Categories: , ,
  • # LGM Pharma is a Pramipexole CAS# 104632-26-0 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Pramipexole
  • CAS #: 104632-26-0
  • Mode of Action:

    The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum.

  • Pharmacodynamics:

    Pramipexole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that Pramipexole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum.

  • Metabolism:

    No metabolites have been identified in plasma or urine.

  • IUPAC: (6S)-6-N-propyl-4, 5, 6, 7-tetrahydro-1, 3-benzothiazole-2, 6-diamine
  • ATC: N04BC05
  • PubChem: 59868
  • DrugBank: DB00413 (APRD00156)
  • Formula: C19H21N5O4
  • Molecular Mass: 211.327
  • Synonyms: (-)-Pramipexole
  • SMILES: CCCN[C@H]1CCC2=C(C1)SC(N)=N2
  • AHFS Code: 28:36.20.08
  • InChl: FASDKYOPVNHBLU-ZETCQYMHSA-N
  • General Reference:

    1. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM: Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995 Jun 23;290(1):29-36. Pubmed

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements